On April 1, 2019 Exicure, Inc. (OTCQB:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, reported that it will present pre-clinical and clinical data for its TLR9 immune system agonist, AST-008, in two poster sessions at the AACR (Free AACR Whitepaper) Annual Meeting 2019 in Atlanta, Georgia from March 29 – April 03, 2019 (Press release, Exicure, APR 1, 2019, View Source;p=RssLanding&cat=news&id=2392886 [SID1234534808]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"On behalf of the Exicure team, we are pleased to announce these two posters which underscore the importance of Exicure’s SNA technology for immune therapy against cancer," said Dr. David Giljohann, Chief Executive Officer of Exicure. "The first poster shows the high potency activation of effector immune cells by our immune system agonist AST-008 after administration of AST-008 to healthy volunteers in a Phase 1 clinical trial. In the second poster, we are pleased to share for the first time, work conducted in collaboration with Celldex Therapeutics showing that Exicure’s TLR9 agonist leads to improved anti-tumor response when combined with CDX-301," said Dr. Giljohann.
The first poster, authored and presented by Exicure scientists, titled: "AST-008, a TLR9 agonist spherical nucleic acid, activated NK cells, T cells, and cytokines in healthy subjects in a Phase 1 clinical trial" demonstrates the utility of Exicure’s proprietary platform technology for targeting TLR9 to upregulate the immune system. Exicure’s drug, AST-008, is now enrolling patients in a Phase 1b/2 trial in patients with advanced solid tumors.
A second poster, to be presented by Celldex scientists, showcases data generated by Celldex Therapeutics, Inc. and Exicure through an ongoing scientific collaboration. The poster, titled: "Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA" highlights improved anti-tumor activity after administration of AST-008 in combination with CDX-301.
Details of the posters:
Title: AST-008, a TLR9 agonist spherical nucleic acid, activated NK cells, T cells, and cytokines in healthy subjects in a Phase 1 clinical trial.
Abstract/Poster No: CT044/1
Date of poster presentation: April 01, 2019, 8:00 AM – 12:00 PM ET
Session Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 17
Title: Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA
Abstract/Poster No: 3217/27
Date of poster presentation: April 02, 2019, 8:00 AM – 12:00 PM ET
Session Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 23